DE69131292D1 - Antikoagulierende proteine - Google Patents
Antikoagulierende proteineInfo
- Publication number
- DE69131292D1 DE69131292D1 DE69131292T DE69131292T DE69131292D1 DE 69131292 D1 DE69131292 D1 DE 69131292D1 DE 69131292 T DE69131292 T DE 69131292T DE 69131292 T DE69131292 T DE 69131292T DE 69131292 D1 DE69131292 D1 DE 69131292D1
- Authority
- DE
- Germany
- Prior art keywords
- factor vii
- modified
- wild
- coagulation cascade
- anticoagulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002429 anti-coagulating effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 7
- 108010023321 Factor VII Proteins 0.000 abstract 7
- 229940012413 factor vii Drugs 0.000 abstract 7
- 239000003146 anticoagulant agent Substances 0.000 abstract 2
- 229940127219 anticoagulant drug Drugs 0.000 abstract 2
- 230000015271 coagulation Effects 0.000 abstract 2
- 238000005345 coagulation Methods 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108010054265 Factor VIIa Proteins 0.000 abstract 1
- 108010000499 Thromboplastin Proteins 0.000 abstract 1
- 102000002262 Thromboplastin Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000035602 clotting Effects 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 abstract 1
- 229940012414 factor viia Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47131390A | 1990-01-29 | 1990-01-29 | |
PCT/US1991/000552 WO1991011514A1 (en) | 1990-01-29 | 1991-01-25 | Anticoagulant proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69131292D1 true DE69131292D1 (de) | 1999-07-08 |
DE69131292T2 DE69131292T2 (de) | 1999-09-30 |
Family
ID=23871126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69131292T Expired - Fee Related DE69131292T2 (de) | 1990-01-29 | 1991-01-25 | Antikoagulierende proteine |
Country Status (8)
Country | Link |
---|---|
US (2) | US5288629A (de) |
EP (1) | EP0521873B1 (de) |
JP (2) | JP3330932B2 (de) |
AT (1) | ATE180834T1 (de) |
AU (1) | AU651573B2 (de) |
CA (1) | CA2074839C (de) |
DE (1) | DE69131292T2 (de) |
WO (1) | WO1991011514A1 (de) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
JPH05506361A (ja) * | 1990-05-17 | 1993-09-22 | ダナ―ファーバー キャンサー インスティテュート インク | 多量体蛋白質に対するトランス―ドミナントサプレッサ遺伝子 |
US6475781B1 (en) | 1990-05-17 | 2002-11-05 | Dana-Farber Cancer Institute, Inc. | Trans-dominant suppressor genes for oligomeric proteins |
US5997864A (en) | 1995-06-07 | 1999-12-07 | Novo Nordisk A/S | Modified factor VII |
US5861374A (en) * | 1991-02-28 | 1999-01-19 | Novo Nordisk A/S | Modified Factor VII |
US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
US20040087498A1 (en) * | 1991-02-28 | 2004-05-06 | Novo Nordisk Health Care Ag | Modified factor VII |
EP1479395A1 (de) * | 1991-02-28 | 2004-11-24 | Novo Nordisk A/S | Modifizierter Faktor VII |
US6039944A (en) * | 1992-02-28 | 2000-03-21 | Zymogenetics, Inc. | Modified Factor VII |
CA2162726A1 (en) * | 1993-05-21 | 1994-12-08 | Kathleen L. Berkner | Modified factor vii |
AU7050994A (en) * | 1993-06-01 | 1994-12-20 | Scripps Research Institute, The | Human mutant tissue factor compositions useful as tissue factor antagonists |
JPH08511794A (ja) * | 1993-06-18 | 1996-12-10 | ハフスルント ニコムド エイ/エス | ▲vii▼因子由来ペプチド |
US5510248A (en) * | 1993-06-22 | 1996-04-23 | The University Of British Columbia | Stable recombinant meizothrombin-like polypeptides |
US6693075B1 (en) | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6017882A (en) * | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
AR017831A1 (es) * | 1997-12-10 | 2001-10-24 | Pioneer Hi Bred Int | Metodo para alterar la composicion de aminoacidos de una proteina nativa de interes, proteina elaborada, y polinucleotido |
US6924359B1 (en) * | 1999-07-01 | 2005-08-02 | Yale University | Neovascular-targeted immunoconjugates |
CA2373735A1 (en) | 1999-07-02 | 2001-01-11 | Genentech, Inc. | Fviia antagonists |
US6586574B1 (en) * | 1999-08-17 | 2003-07-01 | Nn A/S | Stabilization of freeze-dried cake |
IL150692A0 (en) | 2000-02-11 | 2003-02-12 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
AU2001249389A1 (en) * | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6905683B2 (en) * | 2000-05-03 | 2005-06-14 | Novo Nordisk Healthcare A/G | Human coagulation factor VII variants |
US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
EP1319067A2 (de) | 2000-09-13 | 2003-06-18 | Novo Nordisk A/S | Varianten des menschlichen koagulationsfaktors vii |
CZ2003611A3 (cs) * | 2000-09-13 | 2003-08-13 | Novo Nordisk A/S | Varianty lidského koagulačního faktoru VII |
WO2002055110A2 (en) * | 2000-10-25 | 2002-07-18 | Genzyme Corp | Methods for treating blood coagulation disorders |
AU2002218029A1 (en) * | 2000-11-09 | 2002-05-21 | The Scripps Research Institute | Modified factor viia |
PL371800A1 (en) | 2001-03-22 | 2005-06-27 | Novo Nordisk Health Care Ag | Coagulation factor vii derivatives |
US7052868B2 (en) * | 2001-09-27 | 2006-05-30 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
CA2461003A1 (en) | 2001-09-27 | 2003-04-03 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US6960657B2 (en) * | 2001-11-02 | 2005-11-01 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
JP2005530683A (ja) | 2001-12-21 | 2005-10-13 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第vii因子ポリペプチドの液体組成物 |
US7164002B2 (en) | 2002-02-06 | 2007-01-16 | Genentech, Inc. | FVIIa antagonists |
EP1499719B1 (de) * | 2002-04-30 | 2010-11-17 | Bayer HealthCare LLC | Faktor vii oder faktor viia polypeptidvarianten |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
MXPA04012496A (es) * | 2002-06-21 | 2005-09-12 | Novo Nordisk Healthcare Ag | Glicoformos del factor vii pegilados. |
CN101912601B (zh) | 2002-06-21 | 2012-08-29 | 诺和诺德医疗保健公司 | 因子vii多肽的稳定化固体组合物 |
US6911323B2 (en) * | 2002-09-25 | 2005-06-28 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
EP1549677B1 (de) * | 2002-09-30 | 2011-04-13 | Bayer HealthCare LLC | FVII- ODER FVIIa-VARIANTEN MIT ERHÖHTER KOAGULATIONSWIRKUNG |
US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
RU2364626C2 (ru) | 2003-03-18 | 2009-08-20 | Ново Нордиск Хелт Кэр Аг | Способ получения, способ очистки и способ стабилизации полипептидов фактора vii, ix и x |
MXPA05009914A (es) * | 2003-03-18 | 2006-01-09 | Novo Nordisk Healthcare Ag | Composiciones farmaceuticas acuosas, liquidas de polipeptidos del factor vii. |
DE602004021099D1 (de) | 2003-03-20 | 2009-06-25 | Bayer Healthcare Llc | Fvii oder fviia varianten |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
BRPI0409936A (pt) * | 2003-05-23 | 2006-04-25 | Novo Nordisk Healthcare Ag | uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico |
BRPI0411650A (pt) * | 2003-06-19 | 2006-08-08 | Maxygen Holdings Ltd | variante polipeptìdica do fator vii (fvii) ou do fator viia (fviia), sequencia de nucleotìdeos , vetor de expressão, célula hospedeira, composição, uso de uma variante, e, método para tratar de um mamìfero tendo uma doença ou um distúrbio em que a formação de coágulo seja desejável |
WO2005002615A1 (en) * | 2003-07-01 | 2005-01-13 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of factor vii polypeptides |
KR101293503B1 (ko) | 2003-08-14 | 2013-08-07 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 vii 폴리펩티드의 액상 수성 약학적 조성물 |
CN1863908B (zh) | 2003-09-09 | 2010-08-04 | 诺和诺德医疗保健公司 | 凝固因子ⅶ多肽 |
JP2007511604A (ja) * | 2003-11-18 | 2007-05-10 | アイコニック セラピューティクス インコーポレイティッド | キメラタンパク質の均質製剤 |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
RU2373953C2 (ru) * | 2003-12-19 | 2009-11-27 | Ново Нордиск Хелс Кеа Аг | Стабилизированная композиция, содержащая полипептид фактора vii |
EP1713906A2 (de) * | 2004-02-03 | 2006-10-25 | Novo Nordisk Health Care AG | Keine funktionelle lipid-membran-bindungsdomäne aufweisende koagulationsfaktor vii/viia-varianten |
US20080255026A1 (en) * | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
WO2007031559A2 (en) | 2005-09-14 | 2007-03-22 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
EP1929005A1 (de) * | 2005-09-21 | 2008-06-11 | Novo Nordisk Health Care AG | Menschliche gerinnungsfaktor-vii-polypeptide |
US8461115B2 (en) * | 2006-03-16 | 2013-06-11 | Stellaris Pharmaceuticals Aps | Methods for local treatment with factor VII |
WO2008009635A2 (en) * | 2006-07-17 | 2008-01-24 | Novo Nordisk Health Care Ag | Factor viia analogues with increased activity for treating thrombocytopenia |
PT2147096E (pt) * | 2007-04-13 | 2015-07-21 | Catalyst Biosciences Inc | Polipéptidos do factor vii modificados e suas utilizações |
MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子vii多肽和其用途 |
AR077041A1 (es) | 2009-06-09 | 2011-07-27 | Prolong Pharmaceuticals Inc | Composiciones de hemoglobina. metodos. |
TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
WO2021030787A1 (en) | 2019-08-15 | 2021-02-18 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
DE3684546D1 (de) * | 1985-04-22 | 1992-04-30 | Genetics Inst | Herstellung mit hoher leistung des aktivfaktors ix. |
US4959318A (en) * | 1985-06-27 | 1990-09-25 | Zymogenetics, Inc. | Expression of protein C |
US5258288A (en) * | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
DK323587D0 (da) * | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
JP2799316B2 (ja) * | 1987-06-12 | 1998-09-17 | ヘキスト・マリオン・ルセル株式会社 | 雑種ヒトプロテインcおよびその遺伝子工学的製法 |
US4994371A (en) * | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
US5023236A (en) * | 1988-04-07 | 1991-06-11 | Corvas, Inc. | Factor VII/VIIA active site inhibitors |
-
1991
- 1991-01-25 AT AT91904449T patent/ATE180834T1/de not_active IP Right Cessation
- 1991-01-25 WO PCT/US1991/000552 patent/WO1991011514A1/en active IP Right Grant
- 1991-01-25 JP JP50486391A patent/JP3330932B2/ja not_active Expired - Fee Related
- 1991-01-25 DE DE69131292T patent/DE69131292T2/de not_active Expired - Fee Related
- 1991-01-25 CA CA002074839A patent/CA2074839C/en not_active Expired - Fee Related
- 1991-01-25 AU AU73002/91A patent/AU651573B2/en not_active Ceased
- 1991-01-25 EP EP91904449A patent/EP0521873B1/de not_active Expired - Lifetime
-
1992
- 1992-09-21 US US07/951,295 patent/US5288629A/en not_active Expired - Lifetime
-
1993
- 1993-11-12 US US08/152,199 patent/US5824639A/en not_active Expired - Fee Related
-
2001
- 2001-12-26 JP JP2001394519A patent/JP2002247996A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US5824639A (en) | 1998-10-20 |
AU651573B2 (en) | 1994-07-28 |
JPH05500161A (ja) | 1993-01-21 |
EP0521873B1 (de) | 1999-06-02 |
JP3330932B2 (ja) | 2002-10-07 |
CA2074839C (en) | 2000-11-14 |
AU7300291A (en) | 1991-08-21 |
ATE180834T1 (de) | 1999-06-15 |
US5288629A (en) | 1994-02-22 |
DE69131292T2 (de) | 1999-09-30 |
JP2002247996A (ja) | 2002-09-03 |
CA2074839A1 (en) | 1991-07-30 |
EP0521873A4 (en) | 1993-05-05 |
WO1991011514A1 (en) | 1991-08-08 |
EP0521873A1 (de) | 1993-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69131292D1 (de) | Antikoagulierende proteine | |
CA1244763A (en) | Blood coagulation inhibiting proteins, processes for preparing them and their uses | |
JP5037331B2 (ja) | 出血性障害の処置のための第ixa因子 | |
Elg et al. | Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits | |
Bajwa et al. | Thrombin-like and fibrinolytic enzymes in the venoms from the Gaboon viper (Bitis gabonica), eastern cottonmouth moccasin (Agkistrodon p. piscivorus) and southern copperhead (Agkistrodon c. contortrix) snakes | |
ATE57836T1 (de) | Nichtdenaturierte virusfreie biologisch aktive proteinderivate. | |
CA2060507A1 (en) | Factor xa based anticoagulant compositions | |
Gitel et al. | The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications | |
US5922358A (en) | Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications | |
US5637299A (en) | Enhancement of thrombolytic therapy with deglycosylated forms of plasminogen | |
Aronson | Factor IX complex | |
US20110053851A1 (en) | Haemostasis-modulating compositions and uses therefor | |
Weinstein et al. | Enhancement of rabbit protein S anticoagulant cofactor activity in vivo by modulation of the protein S C4B binding protein interaction. | |
US5510248A (en) | Stable recombinant meizothrombin-like polypeptides | |
Ku et al. | Modulation of fibrin clot formation by human serum amyloid P component (SAP) and heparin. | |
JPH07291999A (ja) | 血小板安定化因子ix−フラグメント、その製造方法及びこれを含有する薬剤 | |
Thelin et al. | The action of thrombin on serum albumin | |
Ratnoff | A. The Physiology of Blood Coagulation | |
EP1181046B1 (de) | 10-formyltetrahydrofolate dehydrogenase als therapeutischen mittel | |
EP0326013A3 (de) | Von menschlichem alpha-2-Plasmin-Inhibitor abgeleitete neue Proteine oder Proteine, die diesen ähnlich sind | |
Chamone | Physiological aspects and clinical application of heparin | |
Kline et al. | Purification of components of the plasmin system | |
SUMI et al. | Enzymatic production of acid stable trypsin-plasmin inhibitor (ASTI) in human plasma | |
Bhargava et al. | Characterization of a new potent heparin | |
Swedenborg et al. | Coagulation activity of surface activated plasma in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: VONNEMANN, KLOIBER & KOLLEGEN, 80796 MUENCHEN |
|
8339 | Ceased/non-payment of the annual fee |